Table 2. TEAEs with > 1% proportion of all TEAEs.
| AE term | % of all TEAEs (100% = 621) |
|---|---|
| Headache | 14.8 |
| Dyspepsia | 4.5 |
| Flushing | 4.3 |
| Fatigue | 2.7 |
| Nasopharyngitis | 2.3 |
| Nasal congestion | 2.3 |
| Ocular hyperemia | 2.1 |
| Catheter-site pain | 2.1 |
| Back pain | 2.1 |
| Nausea | 1.6 |
| Vessel puncture-site reaction | 1.6 |
| Micturition urgency | 1.6 |
| Palpitations | 1.4 |
| Diarrhea | 1.4 |
| Catheter-site swelling | 1.4 |
| Thirst | 1.4 |
| Sinus tachycardia | 1.3 |
| Feeling hot | 1.3 |
| Dizziness | 1.3 |
| Restlessness | 1.3 |
| Myalgia | 1.1 |
| Application-site erythema | 1.0 |
| Oral herpes | 1.0 |
| Subcutaneous hematoma | 1.0 |
| Paranesthesia | 1.0 |
TEAE = treatment-emergent adverse event; AE = adverse event.